The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Global News Feed
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- 4 Bulletproof Ways to Improve Your Immune System Naturally
- 7 ways to keep mosquitoes away from your baby
- How To Live With Less Sugar In Your Diet – Longevity LIVE – Longevity LIVE
- How to live longer: Bacteria in the gut could boost longevity study – Toys Matrix
- World Lipstick Day: A Beauty Guide To The Perfect Pout – Longevity LIVE – Longevity LIVE
- erythropoietic protoporphyria death from mt 7117 trial
- how long numbness after getting teeth pulled
- dr joseph angel de soto
- can filling numbness last a long time
- TIME MAGAZINE ARTICLE : WHAT DID JESUS SAY ABOUT HEAVEN AND HELL
- Medical genetics wikipedia
- numb chin after tooth exytaction
- how long can numbness last after extraction
- how long does it take for numbness to go away after wisdom tooth extraction
- innie vs outie vulva
|Search Immortality Topics:|
Category Archives: BioEngineering
Singapore-based HeMo Bioengineering Receives China’s NMPA Approval for flagship Afentta(TM) Aspiration Catheter – PRNewswire
Stroke is the leading cause of mortality and disability among adults in China and is associated with high incidence, disability, mortality and recurrence rates, as well as high financial costs.Among the types of stroke, Acute Ischemic Stroke ("AIS") accounts for approximately 70% of stroke cases in China and has been associated with a 10% mortality rate within the first 90 days as well as disability rates in more than a third of patients.The National Health Commission ("NHC")'s Healthy China Action (2019-2030) aims to lower mortality rates from cardiovascular and neurovascular diseases to the region of 20%, and more recently, the Bureau of Medical Administration under China's National Health Commission has targeted to increase the rates of reperfusion therapy for acute cerebral infarctions.
Direct aspiration for AIS can achieve efficacious recanalization of neurovascular arteries, achieve timely reperfusion and improve prognosis, and has been globally recommended as a treatment approach.China's leading physician in the field, Dr. Miao Zhongrong, Professor of Interventional Neuroradiology, Neurosurgery, and Neurology and Head of the Department of Interventional Neuroradiology at Beijing Tiantan Hospital (Capital Medical University), commented, "Afentta has demonstrated shorter procedure times, higher recanalization rates, lower disability rates and lower incidence of arterial dissection, presenting a more efficacious, faster and safer treatment option in interventional thrombectomy."
The Afentta intracranial thrombectomy aspiration catheter is the flagship product developed by HeMo Bioengineering (China) Ltd and has achieved the milestone of being China's first domestically-produced aspiration catheter system. Dr. Jack Wang, HeMo's Founder and Chief Technology Officer, commented, "HeMo Bioengineering is committed to bringing together 'smart' resources to serve China's needs in the neurovascular interventional space.With our professional management team of industry veterans and our diversified and global research and education resources, we are well-positioned to continue delivering world-leading, reliable and innovative medical devices."
HeMo has entered into technology partnerships with U.S.-based Imperative Care, Inc. and Tsinghua University's Department of Chemical Engineering, and has embarked on clinical trial collaborations with Beijing Tiantan Hospital (Capital Medical University).HeMo has also obtained patent protections for the proprietary technologies associated with its aspiration catheter system.Moving forward, HeMo is committed to accelerating the rapid development of China and APAC markets' interventional domain.
About HeMo Bioengineering Ltd:
Headquartered in Singapore, HeMo Bioengineering Ltd ("HeMo") is a fast-growing medical device company focused on the R&D and production of innovative medical devices for treating stroke patients.HeMo's current suite of neuro interventional products covers ischemic stroke, haemorrhagic stroke and neuro access. HeMo also has a strong presence in China, with manufacturing facilities in Weihai, Shandong and sales offices in Beijing and Shanghai. With a robust and diversified pipeline of other vascular intervention products under development, HeMo is well positioned to become a leading, global platform company in vascular intervention.
Visit HeMo at http://www.hemocorp.com.
For enquiries, please e-mail [emailprotected].
SOURCE HeMo Bioengineering Ltd
From the President: A Message to the Penn Community: Provost Pritchett to Take Leave of Absence – UPENN Almanac
From the President: A Message to the Penn Community: Provost Pritchett to Take Leave of Absence
May 11, 2021
I am writing to share with you the news that our dear friend and colleague, Provost Wendell Pritchett, will be taking a medical leave of absence from his responsibilities here at Penn, beginning July 1, 2021 through the end of the fall 2021 semester. Wendell has been dealing with some health issues that, while not life-threatening, require greater attention over the coming months.
As everyone who has had the pleasure of working with him knows, Wendell continues to do an absolutely superb job as Provost. He is an exceptional leader who is universally recognized for his scholarship, teaching, compassion, and commitment to academic excellence and civic engagement. He is also a cherished friend to so many of us here at Penn. We all want Wendell to take the time necessary to tend to his health, and this leave of absence will allow him to do just that.
While Wendell is on leave, Deputy Provost Beth Winkelstein will assume the role of Interim Provost. Wendell appointed Beth as Deputy Provost in June of 2020 after she had served as Vice Provost for Education for five highly successful years. Beth earned her PhD in bioengineering from Duke University and BSE cum laude in bioengineering from Penn as a Benjamin Franklin Scholar. She has taught in the bioengineering department of Penn SEAS since 2002, becoming in that time one of the worlds leading innovators in research on new treatments for spine and other joint injuries. Appointed two years ago as the Eduard D. Glandt Presidents Distinguished Professor, she leads a pioneering Spine Pain Research Lab, mentors students and postdocs, and is chair of The American Society of Mechanical Engineers Board of Editors. She served as co-editor of the Journal of Biomechanical Engineering from 2013-2020.
Wendell and I and everyone who has worked with Beth have great confidence in her ability to step in and lead the Provosts Office while Wendell is on leave. Beth is an exceptional University citizen who is involved in all aspects of our academic, research and student-centered programming. We are very grateful that she is willing to take on this important responsibility.
Please join me in wishing Wendell a speedy return to full health.
Amy Gutmann, President
Biogen will use Gingko Bioworks mammalian cell programming platform to help advance its AAV-based vector manufacturing.
Under the terms of the agreement, Gingko will provide Biogen with access to its cell programming capabilities and platform.
Gingko will use its bioengineering resources and biomanufacturing space to enhance Biogens AAV production titers in its gene therapy manufacturing processes.
Biogen will pay $5 million upfront, but Gingko has the potential to receive $115 million depending on research, development, and commercial milestones.
Biogen says that while AAV-based vectors carry the potential to treat different conditions and are used widely across the industry to develop gene therapies, the current manufacturing process is time-consuming and expensive, which makes it problematic to develop therapies for diseases that have large patient populations and require a high dose.
According to Biogen, Gingko will attempt to solve this challenge by using its mammalian cell programming platform (Bioworks4) to improve the efficacy of AAV-producing plasmid vectors and cell lines. In turn, potentially advancing Biogens novel gene therapies.
We are excited to collaborate with Biogen as they aim to develop treatments that may potentially slow, halt or cure neurological and neurodegenerative diseases and seek to enhance the industry standard for AAV manufacturing, said Jason Kelly, CEO of Ginkgo Bioworks.
Synthetic biology is leveraging the power of living cells to develop the next generation of therapeutics, everything from CAR-T, to CRISPR and gene therapies, which we believe will have a material impact on the lives of many.
This deal comes less than two weeks after Gingko Bioworks added large-scale protein capabilities outside the US through its acquisition of fungal platform technology firm Dutch DNA.
After completing my citation in French sophomore year, I knew that I wanted to pick up just one more foreign language before I graduated. Despite having long had an interest in Japanese and Japanese history, the distance from Dunster House to Northwest Labs where Japanese courses are typically held on campus was just great enough to dissuade me from committing to a 9 a.m. class that met five times a week. Unexpectedly, and abruptly, the pandemic-necessitated shift to online learning removed this constraint. By simply clicking into the same Zoom meeting every day, I was able to learn about Japanese customs and dissect short stories with a group of warm, motivated classmates who have all become good friends. Together, we built a pandemic-era community that helped sustain me through an academic year like none other.
I miss the warm hugs and short, 10-minute conversations you might share with an old friend from a first-year seminar or even pre-orientation as you find yourselves in the basement of Memorial Hall lining up for Fly-By together. These are also the kinds of interactions that have been the hardest to replicate in our virtual social world of late.
When conditions improve and circumstances allow, I look forward to returning to reading rooms and perhaps even having the opportunity to engage with some of the primary sources that I wish I could have accessed as I was finishing my thesis earlier this semester. Of course, when international travel permits, I am also incredibly excited at the prospect of gathering offline with friends I have not been able to see these past 15 months or so.
Follow this link:
The cap (and gown) on a most unusual senior year - Harvard Gazette
Centrifugation-free Sperm Separation Systems Market to witness increasing venture capital investment in Segment: CooperSurgical, Inc., Koek…
Centrifugation-free Sperm Separation Systems market research report provides detailed information on the following aspects: industry size, share, growth, segmentation, manufacturers and progress, main trends, market drivers, challenges, standardization, deployment models, opportunities, strategies, future roadmaps, and Annual forecast till 2027, etc. The report conducted a professional and in-depth analysis of the current situation of the Centrifugation-free Sperm Separation Systems market, including major players such as manufacturers, suppliers, distributors, traders, customers, and investors. The report also helps you understand the dynamic structure of the Centrifugation-free Sperm Separation Systems market by identifying and analyzing market segments.
Combined with important market challenges, the potential of this industry field has been fully explored. The current market conditions and prospects of this segment have also been checked. In addition, key market strategies including product development, partnerships, mergers, and acquisitions will also be studied. Upstream raw materials and equipment and downstream demand analysis are also conducted.
Have a Need More Info, Request Sample PDF of This Research Report:https://www.worldwidemarketreports.com/sample/696097
The major players profiled in this report include
CooperSurgical, Inc., Koek Biotechnology Bioengineering and Medical Services Industry & Trade, Inc., Memphasys Ltd., DxNow, SAR Healthline Pvt. Ltd., Lotus Bio, other prominent players
Market Segments and Sub-segments Covered in the Report are as per below:
Based on Product Type Centrifugation-free Sperm Separation Systems market is segmented into
Migration-sedimentation (MS), Microfluidic Sperm Sorters (MFSSs), Others
Based on the Application Centrifugation-free Sperm Separation Systems market is segmented into
Hospitals & Clinics, Cryobanks, IVF Centers, Others
Regional Coverage of the Centrifugation-free Sperm Separation Systems Market:
Europe, Asia Pacific, Africa, and the Middle East, North America, Latin America
Impact of COVID-19:
The industry is mainly driven by increasing financial incentives and regulatory support from governments around the world. The current Centrifugation-free Sperm Separation Systems market is mainly affected by the COVID-19 pandemic. Most projects in China, the United States, Germany, and South Korea have been postponed. These companies are facing short-term operational problems due to supply chain constraints and the inaccessibility of factories due to the COVID-19 outbreak. Due to the pandemic impact in China, Japan, and India, the spread of COVID-19 is expected to severely affect the Asia-Pacific region.
Get the Covid-19 Impact Analysis, And All updates on Centrifugation-free Sperm Separation SystemsIndustry:https://www.worldwidemarketreports.com/covidimpact/696097
Frequently Asked Questions
What does the report cover?The report incorporates an analysis of factors that promote market growth. The report introduces the competitive landscape of the global market. This also provides a range of different market segments and applications that may affect the market in the future. The analysis is based on current market trends and historical growth data. It includes detailed market segmentation, regional analysis, and industry competition pattern.
Does the report estimate the current market size?The report effectively assesses the current market size and provides industry forecasts. The value of this market in 2019 is $XXX million, and the compound annual growth rate during 2021-2027 is expected to be XX%.(*Note: XX values will be given in final report)
How does the report provide the market size of the market?The report effectively assesses the current market size and provides forecasts for the industry in the form of Value (millions USD) and transaction Volume (Thousands Units)
What market dynamics does this report cover?The report shares key insights on:
It helps companies make strategic decisions.
Does this report provide customization?Customization helps organizations gain insight into specific market segments and areas of interest. Therefore, WMR provides customized report information according to business needs for strategic calls.
Centrifugation-free Sperm Separation Systems Market 2021-2027: Main Highlights
Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provides our diverse range of clients from across all industries with vital decision-making insights to plan and align their market strategies in line with current market trends.
Bioengineering Professors X. Frank Zhang and Wonpil Im have discovered a way to prevent the COVID-19 virus from sticking to receptors on human cells.
Im and Zhang both had experience studying proteins, but when the pandemic hit they shifted their focus. They were inspired to start their research on SARS-CoV-2 spike receptor proteins to contribute to the fight against the pandemic.
Professor Im and I were interested in this new virus and how it worked, Zhang said. We wanted to know why it was so dangerous and infectious.
While Im and Zhang were trying to find a way to prevent the virus, they also faced challenges associated with the pandemic, including a three month partial pause to their research due to lockdowns.
Once they were given permission to start working again in June, they had to pick up the pace of their research in a race against the spread of the virus.
As (scientists) we ask the question: how can our expertise help this issue, Zhang said.
Im and Zhangs research focuses on spike receptors which are branches stemming from the center of the viruss body. These parts of the cell are responsible for bonding with the cells in the human body, and once they have bonded, humans are able to spread and feel the effects of the virus.
Im and Zhangs research prevents the spike receptor from binding to the cells in our body. In their experiments, they would use a COVID-19 spike receptor and would bind it to a human cell. They would then measure how much force it would take to decouple to a receptor from the cell.
What makes Im and Zhangs research unique is that they used an experimental technique created by Zhang.
His technique can measure the strength (of the bond) between the viruss spike protein and the human receptor, Im said.
Along with Zhangs experimental technique, Im used a computational modeling simulation to provide detailed on Zhangs experiment.
Because of their teamwork, their findings have a greater significance and you can come to understand the issues and get a deeper answer, said Biology Professor Vassie Ware.
The results of the experiment would not be possible without Ims expertise in computational model simulations and Zhangs novel single molecule detection method.
Because Im and Zhang were experimenting on how to detach the virus from the cell, their research will most likely be used as a cure to COVID-19 for those who currently have the virus, rather than a preventative method.
Although the study could have groundbreaking implications, Zhang believes that with the time it takes to develop and manufacture a new drug, their study will likely not have a tangible impact on the current pandemic.
The time it takes to create a drug and have it pass through the FDA means that this discovery may not be able to catch this pandemic, but it will be helpful for future outbreaks, Zhang said.
In the meantime, Im and Zhang plan on continuing their research and move onto more infectious and dangerous variants of the COVID-19 virus.